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Bacille Calmette–Guérin (BCG), an attenuated vaccine derived from Mycobacterium bovis,
is the current vaccine of choice against tuberculosis (TB). Despite its protection against
activeTB in children, BCG has failed to protect adults againstTB infection and active disease
development, especially in developing countries where the disease is endemic. Currently,
there is a significant effort toward the development of a newTB vaccine.This review article
aims to address publications on recombinant BCG (rBCG) published in the last 5 years, to
highlight the strategies used to develop rBCG, with a focus on the criteria used to improve
immunological memory and protection compared with BCG. The literature review was
done in April 2013, using the key words TB, rBCG vaccine, and memory. This review dis-
cusses the BCG strains and strategies currently used for the modification of BCG, including:
overexpression of Mycobacterium tuberculosis (Mtb) immunodominant antigens already
present in BCG; gene insertion of immunodominant antigens from Mtb absent in the BCG
vaccine; combination of introduction and overexpression of genes that are lost during the
attenuation process of BCG; BCG modifications for the induction of CD8+ T-cell immune
responses and cytokines expressing rBCG. Among the vaccines discussed,VPM1002, also
called rBCG∆ureC:hly, is currently in human clinical trials. Much progress has been made
in the effort to improve BCG, with some promising candidates, but considerable work is
still required to address functional long-lasting memory.
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INTRODUCTION
Tuberculosis (TB) is an infectious disease caused by Mycobac-
terium tuberculosis (Mtb), an intracellular pathogen that, after
infecting a host, can cause disease or latency. TB continues to kill
some 1.3 million people annually and 2 billion people worldwide
are infected with Mtb (1, 2). The attenuated Mycobacterium bovis
strain, known as Bacille Calmette–Guérin (BCG), is currently the
only TB vaccine approved for human use, but its protective efficacy
remains doubtful (3, 4). BCG was initially obtained from a viru-
lent strain and was developed in France between 1908 and 1921 by
Albert Calmette (1863–1933) and Camille Guérin (1872–1961).
Although BCG is efficient in some regions of the world, such as in
Alaskan American Indians region (5, 6), the protection conferred
by BCG varies between 0 and 80% (7–9), although it has efficacy
in protecting children from severe forms of TB.
To achieve BCG attenuation, more than 10 years of research
with more than 230 serial passages were performed in vitro (10).
This attenuation promoted genomic deletions, that together with
the evolution of M. bovis, resulted in 16 genomic regions of
differentiation (RD1–RD16, plus nRD18), when compared with
the Mtb genome (11, 12). Regarding the region of differentia-
tion lost during attenuation, RD1 is a DNA segment comprising
9.5 kb, which was deleted in all other BCG strains, that encodes
T-lymphocyte epitopes such as ESAT-6, CFP-10, Rv3873, and PPE
protein among others (13); RD2 is a 10.7 kb DNA segment that
encodes many proteins including Mpt64 and CFP-21 (12); RD14
is a 9.1 kb section of DNA encoding proteins of the PE-PGRS
and Rv1771 families (gulonolactone dehydrogenase) (14); RD16
is a 7.6 kb DNA section encoding Rv3405 that is responsible for
colony morphology characteristics and the formation of cell mem-
brane constituents (15); and nRD18, a 1.5 kb segment containing
genes encoding SigI, an alternative RNA polymerase sigma factor,
that was only lost in the strains BCG Pasteur, Phipps, Frappier,
Connaught, and Tice (12). During the BCG attenuation process
and the years that followed, more than 14 sub-strains emerged:
BCG Russia (ATCC 35740), BCG Moreau/Rio de Janeiro, BCG
Tokyo, BCG Sweden, BCG Birkhaug (ATCC 35731), BCG Den-
mark 1331 (ATCC 35733), BCG China, BCG Prague, BCG Glaxo
(ATCC 35741), BCG Tice (ATCC 35743), BCG Frappier (ATCC
35735), BCG Connaught, BCG Phipps (ATCC 35744), and BCG
Pasteur 1173 (16). They are distributed worldwide and have been
used for vaccine development to prevent TB. The main concern
is that BCG administration does not provide a reliable protection
for adults in the developing world, protecting just against the main
causes of infant TB, TB meningitis, and miliary TB (2).
To address the evolution of new recombinant BCG (rBCG)
vaccines, the immunological status goal for such a vaccine should
be defined. This is a controversial issue as there is no consen-
sus as to what is the ideal immune memory phenotype that can
confer protection. For instance, in animal models such as mice,
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both Mtb infection or BCG vaccine induce increased levels of lung
CD4+ effector T cells (phenotype CD44hiCD62LloCCR7lo) as well
as memory cells. The current memory cell phenotypes accepted
are effector memory T cells (TEM, CD44hiCD62LloCCR7lo) and
central memory T cells (TCM, CD44hiCD62LhiCCR7hi) (17–19).
An important cornerstone for protection against TB is interferon
(IFN)-γ production by T cells (20, 21), a cytokine crucial for
stimulation of the microbicidal functions of macrophages. More
recently, some authors have proposed that the desired protective
memory against TB infection should have a central memory char-
acteristic, with polyfunctional ability to produce IFN-γ, tumor
necrosis factor (TNF)-α, and interleukin (IL)-2 cytokines (22)
or a balance between IFN-γ and IL-17 levels to avoid excessive
pathology (23).
The ultimate goal of a vaccine is its protective use in humans;
consequently, the characterization of memory T cells in humans
is also crucial. The major cell surface biomarker expression pat-
tern for human memory T cells with an effector phenotype is
CD45RAhi, CD45ROneg, and CCR7neg, while for central memory
T-cell populations it is CD45RAhi/low, CD45ROneg, and CCR7pos.
A follow-up study conducted among children vaccinated with
BCG showed that specific memory T cells were stimulated and
present in the peripheral blood of those individuals for at least
52 weeks following vaccination (24). It is interesting to observe
that the induced memory cells were polyfunctional (IFN-γ, TNF-
α, and IL-2). Although several studies have characterized the
memory phenotypes induced by BCG, the direct association of
memory T-cell populations with TB protection is still not well-
established. Recently, a long-lasting T-cell memory population
expressing CD127 was associated with Mtb infection and may
correlate with protection shown by some exposed individuals (25).
For this review, we consider the memory T-cell population as those
that have the following phenotypes: CD4+ CD44hi/low CD62Llo or
to be antigen-specific CD4+ IFN-γ producing cells.
A significant limitation of TB vaccine development and testing
is the lack of an optimal animal model that truly reflects human
TB disease and the progress of immune responses. While there
are several new vaccines being developed in different laboratories,
there is a diversity of animal models (mice, rabbits, guinea pigs,
non-human primates) and disease outcomes being used by dif-
ferent laboratories, preventing an adequate comparison between
them. In addition, there is no consensus on the protocol to be used
for vaccination and challenge, with different routes of immuniza-
tion/infection, doses, BCG and Mtb strains, and time periods being
used. Short period of time between vaccination and challenge does
not allow full immunological memory development, thus gener-
ating a bias in the correlation between memory T-cell phenotype
and protection. The most accepted method for evaluating protec-
tion is the determination of the bacterial load following challenge
of vaccinated animals compared to non-vaccinated infected con-
trols. Although colony-forming unit (CFU) counting is a widely
used method, the organs used to assess the bacterial load vary
among researchers, and make it difficult to establish comparisons.
Given these many different parameters, in this review protection
conferred by the different rBCG vaccines was considered when an
overall significant reduction of the bacterial load compared with
wild type BCG was achieved.
The factors that determine the induction of immunological
memory related to BCG are not well-understood. Some assump-
tions are directed to the characteristics of the BCG sub-strains,
which exhibit genotypic and phenotypic differences after the atten-
uation process as well as distinct residual virulence levels, the
number of epitopes of each BCG strain, or the recombination
strategy used for the development of a new vaccine (26, 27).
According to the research tools employed in this study, of all sub-
strains originated after this process the strains most frequently
tested over 5 years were BCG Tokyo (BCG Japan), BCG Tice, BCG
Danish (BCG Denmark/BCG SSI 1331), BCG Pasteur, BCG China
(BCG Shanghai), and BCG Prague. It is also hypothesized that
generation of the immune response and eventually the outcome
of vaccination could be influenced by the type of genetic strain
background used. However, pre-clinical animal and human data
have demonstrated that different strains of BCG confer the same
level of protection (28, 29).
The main strategies used to develop new vaccines are based
on the formulation of subunit vaccines; the production of non-
recombinant viral vector vaccines that can be used as a BCG prime
boost, and the construction of rBCG, which could confer sim-
ilar protection with a better induction of memory than BCG.
Methods to construct rBCG include overexpression of promising
Mtb immunodominant antigens expressed by BCG, such as α-
crystallin: HspX protein and antigen 85 (Ag85) complex proteins
(Ag85A,Ag85B, and Ag85C) (30); insertion of Mtb immunodomi-
nant antigens absent on BCG, such as those encoded by RD1, RD2,
RD3, RD14, RD15, RD16, and nRD18 genes (27); combination
of overexpression with reintroduction of genes lost during BCG
attenuation; and BCG modification to induce CD8+ T immune
response proteins and cytokines (Tables 1 and 2).
Therefore, the aim of this review was to analyze which fac-
tors associated with rBCG could induce long-lasting memory and
promote better protection compared with conventional BCG.
DOES BCG EPITOPE NUMBER INFLUENCE THE INDUCTION
OF MEMORY AND PROTECTION OF rBCG VACCINES?
As stated by Zhang et al. (27), the number of epitopes in a partic-
ular strain can be important for the development of an enhanced
vaccine that could replace BCG. According to this hypothesis, a
strain such as BCG Tokyo has the potential to induce a better
immune response compared with conventional BCG because it
comprises 359 epitopes that can be recognized by lymphocytes
(27). To verify if there is sufficient data to support this hypothesis
in the last 5 years, we selected criteria as summarized in Table 1.
The different rBCG vaccines were compared according to their
ability to improve protection by reducing the bacterial load rela-
tive to wild type BCG and to generate specific memory CD4+ T
cells. Three different published studies using rBCG Tokyo, which
contains a high number of epitopes, showed better protection than
BCG, which was associated with the recombinant generation strat-
egy: overexpression and reintroduction of lost genes, as well as the
presence of cytokines (Table 1). Nevertheless, the strain that has
been most widely used in the last 5 years is BCG Danish (BCG
Denmark/BCG SSI 1331), which has approximately 329 epitopes,
and provides improved protection and long-lasting memory when
associated with the overexpression of Mtb antigens. Two rBCG
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Table 1 | BCG sub-strains genetic background used for recombinant BCG vaccines development and ability to induce memory and protection
against tuberculosis.
Sub-strains RDsa Epitopes Nob Protection better than BCG?c Memory?d Reference
Tokyo/Japan RD1 359 3 Yes Yes (31, 32)
Yes No (33)
Pasteur RD1, RD2, RD14, nRD18, 331 6 Yes No (34)
No Yes (35)
No No (36–38)
Danish/Denmark RD1, RD2 329 11 Yes Yes (39)
No Yes (40)
Yes No (41–45)
No No (46–48)
Tice RD1, RD2, nRD18 328 2 Yes Yes (49)
Yes No (50)
China/Shanghai RD1, RD2 321 6 Yes No (51)
No No (52–56)
Prague RD1, RD2 318 3 Yes No (23)
No No (57, 58)
aRD, region of difference.
bNumber of publications in the last 5 years.
cProtection was evaluated by CFU analyses and considered when the bacterial load of challenged animals were lower than wild type BCG-vaccinated animals.
dMemory was defined as CD4+ CD44hi CD62Llo or CD4+ IFN-γ producing T cells specific immune responses.
Table 2 | Description of strains and antigens used in the papers visited for this review.
Reference Model Strain Antigen Challenge Protectiona
(31) Mice BCG Tokyo rBCG1:Ag85B–CFP10(rBCG1)/BCG2:Ag85B–CFP10–IL-12 (rBCG2) No > (Ex vivo)
(49) Human BCG Tice rBCG30 (Ag 85B) No NE
(46) Guinea pigs BCG Danish rBCG–E6 (ESAT-6) 50–100 bacilli of Mtb >
(41, 42) Guinea pigs BCG Danish rBCGacr 50–100 bacilli of Mtb >
(39) Mice BCG Danish BCG:HspX/rBCG:85B 106 CFU of Mtb >
(53) Mice BCG China rBCG–AE 106 CFU of Mtb <
(58) Mice BCG Prague rBCGureC:hly or rBCGureC:hly 102 CFU of Mtb =
(45) Mice BCG Danish BCG: rBCG–Ag85B–Mpt64–Mtb8.4 106 CFU of Mtb >
(47) Mice BCG Danish rBCG:Ag85B–ESAT-6–Rv2608 No NE
(33) Monkey BCG Tokyo rBCG–Ag85A 3000 CFU of Mtb >
(48) Monkey BCG Danish rBCG AFRO-1 No NE
(55) In vitro BCG China rBCG:Quimera 85B+ESAT-6 No NE
(34) Mice BCG Pasteur rBCG:PE–MPT64/rBCG/HSP60MPT64 ~200 CFU of Mtb >
(23) Mice BCG Prague rBCG∆ureC:hly+ 200–400 CFU of Mtb >
(51) Mice BCG China rBCG: Ag85A/rBCG:Ag85B/rBCG:Ag85A–Ag85B 106 CFU of Mtb >
(52) Mice BCG China rBCG: Ag85A–ESAT-6/rBCG: Ag85A/rBCG: ESAT-6 No NE
(40) Monkey BCGDanish AFRO-1, Ag85A, Ag85B e TB10.4. 500 CFU of Mtb >
(37) Mice BCG Pasteur rBCGs:BCG:Ag85c, BCG:INV, BCG:PPE, BCG:FBP e BCG:CFP 20 bacilli of Mtb =
(57) Mice BCG Prague rBCG∆ureC:hly+) No NE
(38) Mice BCG Pasteur rBCG: pHspX–Ag 85B 100 bacilli of Mtb/lung =
(56) Mice BCG China rBCGs:BCG:GM-CSF/BCG:ESAT-6/BCG:GMCSF–ESAT-6 No NE
(32) Mice BCG Tokyo rBCG–85B–IL-15/rBCG–85B 2×105 CFU of Mtb =
(44) Guinea pigs BCG Danish rBCG–85C 500 bacilli of Mtb >
(59) Human BCG Danish BCG ∆ureC:hly HmR No NE
aProtection was evaluated by CFU analyses and considered when the bacterial load of challenged animals were lower than wild type BCG-vaccinated animals; >,
superior than BCG; =, protection similar to BCG; –, less protection than BCG; NE, not evaluated.
References published and indexed in PubMed from 2008 to April 2013.
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Tice (328 epitopes) vaccine constructions also demonstrated good
induction of protection but only one induced memory. Based on
those publications, it appears that the genetic background of the
BCG strains (number of epitopes) does not have a major role in
inducing/improving protection and memory.
Contrary to Zhang et al. (27), other studies support the idea
that recombinant antigen selection expressed by BCG, and not
the BCG strain background, is the significant point to be consid-
ered in the construction of an improved vaccine with enhanced
induction of memory and protection (32, 34, 46). Moreover, it
appears that overexpression of certain antigens in rBCG are criti-
cal for enhanced induction of memory and protection compared
with BCG.
One limitation of this study is that when analyzing studies
only published in the last 5 years, the conclusions might be biased
because important work addressing whether the BCG strain back-
ground (epitope number) or selected antigen were important
for enhanced memory and protection may have been published
earlier.
DOES THE QUANTITY OF Mtb ANTIGENS INCORPORATED IN
BCG RESULT IN GREATER PROTECTION AND MEMORY
DEVELOPMENT?
rBCG VACCINES SUPER EXPRESSING Mtb IMMUNODOMINANT
ANTIGENS
An important strategy used for the construction of a new TB
vaccine is the development of an rBCG super expressing Mtb
immunodominant antigens, such as proteins from the Ag85 Com-
plex, HspX protein, and the association of both proteins in one
vaccine construction, which represents a favored approach for TB
vaccine construction (44).
Some of the most important antigens used to construct
rBCG vaccines are those from the Ag85 Complex that consists
of Ag85A (Rv3804c), Ag85B (Rv1886c), and Ag85C (Rv0129c),
encoded by fbpA, fbpB, and fbpC2 genes, respectively, and with
molecular weights between 30 and 32 kDa (60). Proteins of
Ag85 complex have mycolyltransferase activity, thus they play
a role in mycolate production and construction of the Mtb
cell wall, which is important for maintaining Mtb integrity and
pathogenesis (61).
The protein Ag85B, used for construction of the vaccine
rBCG:30 (r30–Ag85B), generated protection in guinea pigs after
challenge with Mtb (62, 63). A phase I clinical trial of rBCG:30
in human volunteers induced central and effector memory CD4
and CD8 T cells specific for Ag85B (49). Currently, this vac-
cine is no longer being tested on humans. The same anti-
gen was used by Tullius et al. (50) who developed a mutant
rBCG, rBCG(mbt)30, resulting in a strain unable to synthesize
mycobactin and exoquelin molecules that are essential for iron
acquisition. The vaccine induced greater protection than conven-
tional BCG. Another approach was to design an rBCG pantothen-
ate auxotroph, rBCG(panCD)30. Both vaccines, rBCG(mbt)30
and rBCG(panCD)30, were attenuated to a higher degree than
BCG and induced potent protective and cell-mediated immunity
in guinea pigs (50). These vaccines may have the potential to pro-
vide a safe alternative for HIV positive individuals since BCG is
not indicated for use in immunocompromised individuals.
rBCG:30 and other vaccines overexpressing Ag85B were better
at conferring protection and memory than BCG. Ag85B (30 kDa)
is the most abundant protein of the Ag85 complex, and is the most
abundant extracellular protein of Mtb, responsible for nearly one-
quarter of the total extracellular protein in broth culture (64).
In addition, Ag85B has a high affinity for T-cell recognition, can
induce a type Th1 immune response with IFN-γ production,
and has a good protective capacity when used in DNA vaccine
strategies (65).
Ag85C is also a major secretory protein and immunodomi-
nant antigen, being strongly recognized by sera from TB patients.
Indeed, it is responsible for almost 40% of the mycolate content
of Mtb and its mycolyltransferase activity cannot be substituted
by Ag85A or Ag85B (66). For this reason, Jain et al. (44) devel-
oped an rBCG expressing Ag85C under the transcriptional control
of mycobacteria promoters. Reduced granulomatous infiltration
and granuloma formation were observed when compared to a
group immunized with BCG and the protection (reduced bacte-
rial load in lungs and spleen compared with ancestor BCG) was
associated with reduced levels of IFN-γ, TNF-α, IL-12, and TGF-
β mRNA compared to BCG. However, high levels of inducible
nitric oxide synthase (iNOS) were observed compared with BCG.
Furthermore, previous studies with DNA vaccines using Ag85C
demonstrated the reduced production of IL-2 and IFN-γ with
insufficient protection when animals were challenged with M.
bovis BCG (67). Hence, it is important to stress that both the
type of antigen and its expression in a suitable vector (BCG itself)
is important to confer good protection status. The study by Lozes
et al. used the BCG Danish strain, which may have contributed to
the disappointing results. Unfortunately, the study did not provide
information regarding the ability to generate memory cells.
Ag85A is strongly recognized by T lymphocytes to induce IL-2
and IFN-γ production (67). Immunization of mice and guinea
pigs with rBCG:Ag85A promoted the reduction of pulmonary
pathology severity and increased protection in lungs and spleen
against infection (68). Consequently this vaccine was also tested
in Macaca mulatta, and, after challenge, the group immunized
with rBCG:Ag85A developed light to moderate pneumonia, while
the non-vaccinated group developed multilobar pneumonia, lym-
phadenopathy, and atelectasis. In addition, its protective capacity
was previously appraised in a DNA vaccine system with Ag85A
(69). It was shown that rBCG–Ag85A induced higher protective
efficacy than the parental BCG Tokyo strain (33). In that study,
a strategy of over expressing the antigen in addition to the use
of a BCG strain containing more natural epitopes was employed
(Table 1). Hence, this could justify the potential of this vaccine for
further studies to measure memory induction.
The construction of rBCG expressing single proteins resulted
in promising results. Following those studies, significant progress
was made with the construction and testing of recombinant fusion
proteins, combining two or more protein coding regions from one
or more Mtb proteins, because the combined use of antigens might
enhance protective efficacy compared with rBCG expressing only
one antigen.
To analyze this hypothesis, Wang et al. developed three vaccine
constructions: rBCG:Ag85A (A), rBCG:Ag85B (B), and rBCG:AB,
which were used to immunize mice. The vaccine containing fusion
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antigens, rBCG:AB, showed better protection after challenge with
Mtb, when compared with BCG or rBCG expressing Ag85A or
Ag85B alone. Six and 24 weeks after vaccination, splenocytes of
mice immunized with rBCG:AB stimulated with specific anti-
gen secreted more IFN-γ than splenocytes from mice immunized
with the other rBCG (51). Regrettably, no memory response was
evaluated in that study, probably because memory induction was
already known for rBCG:Ag85B (49). However, no studies using
rBCG expressing Ag85A have assessed memory responses, so it
would be meaningful to verify whether Ag85A could contribute to
enhanced memory responses. Although an approach using recom-
binant fusion proteins is valuable for protection against challenge
with Mtb, additional studies regarding the induction of functional,
long-lasting memory is also required for the development of new
vaccines.
Another antigen frequently used for recombinant expression
in BCG is the HspX protein (Rv2031c, also known as α-cristalin,
molecular weight 16 kDa), a heat shock protein encoded by the
acr gene (70). This protein is abundantly produced during the
latent or persistent Mtb metabolic condition. Shi et al. developed
a rBCG over expressing the immunodominant Mtb antigen, HspX
(rBCG:X) and demonstrated that rBCG:X provided enhanced and
longer lasting protection against Mtb infection than BCG, as evi-
denced by high levels of IFN-γ production, low bacterial load
in tissues, and reduced lung pathology. This was associated with
elevated levels of anti-HspX antibodies during week 6 and 24
(168 days) after rBCG:X immunization, indicating that BCG:X
might persist longer in vivo than BCG (39).
Additionally, results obtained by Shi et al. demonstrated that
expression of HspX by BCG could improve its biological effects,
which might explain the higher expression of Ag85B in the
supernatant and lysate of cells after infection with rBCG:X com-
pared with that by BCG (39). This theory was also corroborated
by Kong et al. (38) who constructed an rBCG expressing Mtb
Ag85B under the control of a HspX promoter. The expression
and immune response to Ag85B was modulated by the HspX
promoter. For example, rBCG:PhspX-85B induced intense spe-
cific Ag85B T-cell proliferation and IFN-γ production 3 weeks
after infection. Increased cell proliferation and IFN-γ produc-
tion was observed after 12 weeks indicating long-lasting cell-
mediated immunity. Despite the intense induction of immune
cell responses, the protection in lungs and spleen induced by
this vaccine was similar to that by BCG. This indicated that in
a model of Ag85B expression under control of a different pro-
moter, there was no improvement in protective efficacy (38).
Although Ag85C is responsible for more than 40% of the myco-
late present in the mycobacteria cell wall (61), evidence suggests
that Ag85B is critical for enhanced BCG induction of memory and
protection (49, 50).
The use of fusion proteins has generated great expectations
in the scientific community, nonetheless, the use of combined
proteins yielded no better memory than BCG, according to the
present accepted parameters, generating only better protection.
The increased protection observed among the recombinant vac-
cines cannot be the only improvement desired for the development
of a new vaccine, as vaccination of available animal models to
study new vaccines to TB does not eliminate all Mtb from the
tissues of challenged animals. Therefore, new definitive protection
parameters are needed.
ASSOCIATION OF OVEREXPRESSION AND REINTRODUCTION OF
ANTIGENS LOST DURING THE ATTENUATION PROCESS
Some virulence regions, such as RD1, were lost during the BCG
attenuation process. RD1 is absent in all BCG sub-strains, but
present in virulent strains and clinical isolates of M. bovis and
M. tuberculosis. The association of Mtb genes lost in the M. bovis
attenuation process within rBCG has been used to improve vac-
cine efficacy (11). The collection of well-defined T-cell antigen
epitopes has been a widely used strategy for the construction of
new vaccines. This collection is based on the reintroduction of
proteins whose gene regions were deleted during the attenuation
process and include the 10 kDa culture filtrate protein (CFP-10,
Rv3874), ESAT-6, PPE family protein (Rv3873), INV (Rv1474),
and MPT64.
When evaluating the induction of immune responses, vaccine
constructions containing antigenic epitopes have been the most
successful, although most studies did not evaluate the protec-
tion or memory induced by these vaccines. Vaccine constructs
using antigen epitopes were good inducers of antigen-specific
Th1 (IFN-γ) immune responses, IgG2a production, and delayed
type hypersensitivity responses compared with BCG. Conversely,
some recombinant vaccines (BCG:CFP, BCG:FBP, BCG:PPE, and
BCG:INV) showed protection similar to that of BCG (37). Only
rBCG vaccines expressing MPT64 antigens fused to a PE antigen
(HPE–∆MPT64–BCG) showed superior protection than those
immunized with BCG. This protection was associated with CD4
and CD8 T-cell induction and the emergence of a specific MPT64
T-cell clone (34). Despite use of the same BCG strain in the
two studies, the differences in protection observed indicate the
importance of antigen choice.
When using proteins of the Ag85 complex, Qie et al. (45) com-
pared the protective efficacy of rBCG–AMM (BCG expressing
Ag85B–MPT64190–198–Mtb8.4) with BCG. Animals vaccinated
with rBCG–AMM generated more antigen-specific CD4 and CD8
T cells than those vaccinated with BCG and showed a more effi-
cient response that protected mice challenged with H37Rv Mtb
strain. Moreover, rBCG–AMM was superior to BCG in reducing
the severity of disease in the target organs such as lungs and spleen,
indicating that rBCG–AMM could be a potential vaccine candi-
date for further studies. Again, this vaccine was not evaluated for
memory induction.
Some rBCG vaccines designed over the past 5 years combined
the ability to generate strong immune responses to Ag85 proteins
using the antigen ESAT-6 (47, 52, 55). Of these studies, only one
addressed protection and memory development. Deng et al. (52)
constructed an rBCG expressing the fusion protein Ag85A–ESAT-6
(rBCG–AE) and this vaccine induced more potent immunogenic-
ity than native BCG in mice and induced a shift toward a Th1 type
immune response with an increase in the ratio of CD4 and CD8 T-
cell subsets. Thus, rBCG–AE elicited long-lasting and stronger Th1
type cell-mediated immune responses than BCG. They further
evaluated the protective efficacy conferred by rBCG–AE against
Mtb infection in BALB/c mice (53). An rBCG vaccine express-
ing ESAT-6 alone did not exceed the parental BCG vaccine for
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protection from Mtb H37Rv infection. The vaccine was developed
using a BCG China strain, while others used BCG Tokyo, BCG
Danish, or BCG Pasteur. As previously stated, vaccine construction
over expressing proteins of the Ag85 Complex seem to have better
protection efficacy than BCG, while rBCG–ESAT-6 induced pro-
tection similar or even inferior to BCG. However, using combined
epitopes from proteins of the Ag85 complex or other proteins
and ESAT-6 improved macrophage activation and antigen presen-
tation (55), and strong humoral and cellular immune responses
were induced (47), although protection or memory generation was
not addressed.
The development of rBCG vaccines that re associated with
or reintroduced genes lost during BCG attenuation appears to
improve protection and memory most frequently when proteins
from the Ag85 complex are associated with the fusion protein. This
observation could be biased as Ag85 proteins are most frequently
used in the development of rBCG vaccines. The combined results
suggest that these genes are evolutionary maintained by Mtb to
induce strong immune responses in animals and humans, inde-
pendent of the type of BCG strain used. Most studies presented
here did not evaluate functional memory, a crucial step for the
development of a long-lasting protective vaccine.
rBCG VACCINE EXPRESSING MAMMALIAN CYTOKINES AND Mtb
PROTEINS
Cytokines play a central role in the immune system and have mul-
tiple effects on different immune cells. IL-2, for example, has been
used for the treatment of some diseases, including TB, but toxic-
ity related to high doses has restricted its use. A solution to that
problem was the expression of rIL-2 and other cytokines by BCG
(71). Another example is IL-15, an important cytokine that main-
tains survival and proliferation of CD8+ T cells with a memory
phenotype (72). To develop new vaccines capable of improv-
ing BCG vaccination, some research strategies have included the
use of rBCG expressing IL-2, IL-12, IL-15, and GM-CSF, among
others.
Recombinant vaccines expressing cytokines induced effector
polyfunctional CD8 T cells and CD4 T cells (producing IFN-γ,
IL-2, and TNF-α), as well as humoral immune responses with
increased specific IgG2a/IgG1 levels [(32) rBCG–Ag85B–IL-15;
(31) BCG: Ag85B–CFP10–IL-12; (56) rBCG: GMCSF–ESAT-6].
Among the types of vaccines, those that expressed IL-15 and IL-
12, were most successful as they induced CD8+ T (CD8+ CD44hi
CD62Llo) and CD4+ T (CD4+ CD44hi CD62Llo) memory
cells (31, 32).
Although these vaccines showed better protection than BCG,
the rBCG–Ag85B–IL-15 vaccine was more promising because it
generated a greater induction of memory CD8 T cells than mem-
ory CD4 T cells, in support of the theory that CD8 T cells rather
than CD4 T cells are important for long-lasting protection against
TB (32). It is important to note that despite the positive influ-
ence of IL-15 in inducing memory cells, in vivo administration
after priming with rBCG followed by challenge with Mtb, did not
induce increased numbers of CD8 T memory cells, a phenomenon
only seen when IL-15 is expressed by rBCG (32).
Thus, the induction of CD8+T cells and polyfunctional CD8+
and CD4+ T cells (producing IFN-γ, IL-2, and TNF-α) are
responsible for the improvement of protection generated by rBCG
while the secretion of ILs might play an important role in the
proliferation and maintenance of memory T cells.
BCG MODIFICATION: INDUCTION OF CD8 T IMMUNE
RESPONSES
Mtb and BCG preferentially localize inside antigen presenting cell
(APC) phagosomes, such as macrophages and dendritic cells. This
localization dictates antigen traffic via MHC-II, which results in
the preferential stimulation of CD4 T cells. CD8 T cytolytic lym-
phocytes (CTLs) are essential for the clearance of intracellular
Mtb infection since CTLs kill cells and bacteria through secre-
tion of cytolytic and antimicrobial effector molecules (perforin
and granulysin). Mtb induced apoptosis in infected cells, result-
ing in vesicles that transport mycobacteria antigens, which can be
captured by local dendritic cells that cross present MHC-I and
MHC-II, that stimulate CD8 and CD4 T cells, respectively (73). It
is also acknowledged that BCG is a weak inducer of apoptosis and
thus activates CD8 T cells to a lesser extent (57, 73). Thus, in an
attempt to improve BCG, rBCG vaccines have been developed to
express listeriolysin (Hly) from Listeria monocytogenes (74) in the
membrane, in combination with deletion of the Urease C (ureC)
gene (rBCG∆ureC:hly). One mechanism of BCG employs to sur-
vive phagosomes is pH neutralization through ureC activity. To
induce apoptosis, Hly requires an acidic pH. The ureC mutant
rBCG allows phagolysosome pH acidification to occur naturally
(74). Using this vaccine protocol, Reece et al. (58) selected anti-
gens based on their expression in response to nutrient deprivation
(Rv2659c), hypoxia (Rv1733c), or disease reactivation (Rv3407)
and transformed rBCG∆ureC:hly with plasmids containing these
antigens, rBCG∆ureC:hly (pMPIIB01). The improved perfor-
mance of this vaccine was demonstrated by a lower bacterial load
in the spleen of infected mice (58). In addition, it induced Th-
17, CD4+, and CD8+ T-cell responses and increased protection
compared with BCG (23, 57). This vaccine is the most promising
rBCG vaccine generated and it finished a phase I clinical trial for
safety with great success. It is currently being tested in newborns
in a phase II clinical trial (59). Although this vaccine aimed to
improve T CD8 responses, the induction of specific CD4 T cells
secreting IFN-γ as well as polyfunctional T CD4 responses were
observed in vaccinated healthy humans.
In a similar approach to obtain a vaccine inducing increased
CD8 T-cell responses, an rBCG, rBCG AFRO-1 (BCG express-
ing Ag85A, Ag85B, and TB10.4) was developed followed by two
boosts with AERAS-402 [adenovirus vaccine 35 (rAd35) express-
ing Ag85A, Ag85B, and TB10.4]. AFRO-1 BCG expresses per-
fringolysin O, which allows BCG to escape to the cell cytosol,
promoting antigen processing and presentation via MHC-I. After
priming with rBCG AFRO-1, there was delayed but strong IFN-γ
production 1 week after boost with AERAS-402, as well as strong
proliferation of CD4 and CD8 T cells (48). This vaccine promoted
longer survival and IFN-γ production; however, no difference
in lung and spleen bacterial load between the groups vaccinated
with BCG or AFRO-1 (also known as AERAS-422) was observed
(43). Although a promising vaccine, AERAS-422 was terminated
because of the development of shingles in some study participants
that occurred during a phase I clinical trial (75).
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The strategy of BCG modification for the induction of CD8
T specific immune responses has had a great impact, as the
recombinant vaccine rBCG∆ureC:hly is in a clinical trial1.
CONCLUSION AND FUTURE PERSPECTIVES
Bacille Calmette–Guérin has been used for almost 100 years, with
more than eight million doses used. However, TB incidence has
shown a slow decrease during the last decade, mainly due to the
increase of multi drug resistant strains and HIV co-infection (6).
Two main cautions of BCG vaccine use are associated with its
variable efficacy and immunity against Mtb infection resulting
in a large pool of latently/persistently infected individuals. Fur-
thermore, BCG might induce better protection among individuals
from regions with lower environmental mycobacterial contam-
inations and lower TB rates. Development of a new vaccine or
improvement of BCG to protect against TB is not an easy task,
once the natural infection per se does not induce protection or
long-lasting T or B functional memory cells since it does not avoid
re-infection. It appears that the coevolution between mycobacteria
and humans favors the mycobacteria. Over the past 5 years, several
attempts were conducted to develop rBCGs (Table 2). Improve-
ment of BCG remains the best choice for the rational design of a TB
vaccine. This review sought to discuss recent TB studies advancing
the rBCG strategy. The main purpose for developing rBCG is to
design a vaccine capable of inducing long-lasting functional mem-
ory with protection similar or superior to that of BCG. In addition,
BCG is a strong inducer of CD4+ T cells but it is an insufficient
stimulator of CD8 T cells. The most effective rBCG vaccination
strategies in animal models and human clinical trials to date were
those that stimulated both CD4+ T and CD8+ T cells to produce
Th1-associated cytokines and induce cytotoxic functions [(24, 76),
see text footnote 1].
It is recognized that protein combinations, such as fusion pro-
teins, as well as the expression of these proteins by different
expression vectors are important strategies in the development
of rBCG vaccines with an enhanced efficacy compared with BCG.
Nevertheless, the vaccine approach of super expressing Mtb pro-
teins in BCG, such as rBCG:30, which expresses only Ag85B, to
induce central memory and more desirable protection than BCG,
is useful (49). This plasmid-based vaccine passed a phase I clin-
ical trial and is currently on hold awaiting the development of
auxotrophic BCG strains to avoid the use of antibiotic resistance
genes (see text footnote 1).
An intriguing point is that an rBCG vaccine currently in a phase
II human clinical trial does not contain Mtb antigens or antigens
lost by BCG during the attenuation process. The rBCG∆ureC:hly
vaccine improved BCG antigen presentation by dendritic cells and
improved processing with the ultimate goal of activating CD8+
T cells. Therefore, this approach might have overcome some of
the evolutionary mycobacteria immunological escape mechanisms
and will allow protective long-lasting functional memory. In time,
whether this vaccine induced better protection against TB will be
determined (77).
Furthermore, the choice of parental BCG strain appears not
to interfere with the recombinant vaccine outcome, because some
1www.clinicaltrials.com
vaccines using the same parental BCG strains had different out-
comes depending on the selected antigen or fusion protein used.
Likewise, the immune response profile of those vaccine candi-
dates that showed better protection than BCG was based upon
CD4 and CD8 T cells with polyfunctional activities. From all stud-
ies reviewed here, only six successfully evaluated immunological
memory in animal models.
The animal models available to study TB vaccines (mice, guinea
pig, or non-human primates) cannot predict the outcome among
vaccinated humans. It is well-known that mice and guinea pigs are
infected by BCG vaccination and the duration of the vaccination
and the time until challenge are crucial to address the persistence
of memory T cells. This premise could be used to justify the low
number of studies that have addressed this issue over the past
5 years.
The real impact of these new vaccines using rBCG or other
strategies that are currently in clinical trials will only be deter-
mined 5–10 years from now. Therefore, studies addressing new
strategies to improve BCG need to be continued.
MATERIALS AND METHODS
STUDY SELECTION AND DATA COLLECTION PROCESS
The search for this review was conducted in April 2013, and was
based on articles published in the previous 5 years (2008–2013).
Articles were searched from the PubMed Database using the fol-
lowing key words: tuberculosis protection and rBCG vaccine with
the intention to address publications showing studies on rBCG
vaccine for tuberculosis. Then further manuscripts were selected
using the key words: tuberculosis protection; rBCG vaccine and
memory. Manuscripts lacking information of the BCG wild type
strain and those that used the boost strategy without evaluating
rBCG responses alone were not included in this review.
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